Franco VR

Language: Spanish
References: 8
Page: s14-16
PDF size: 137.92 Kb.

REFERENCES

1. Shahrizaila N, Lehmann HC, Kuwabara S. Guillain-Barré syndrome. Lancet. 2021; 397 (10280): 1214-1228.

2. Esposito S, Longo MR. Guillain-Barré syndrome. Autoimmun Rev. 2017; 16 (1): 96-101. Available in: https://doi.org/10.1016/j.autrev.2016.09.022

3. Hashim NA, Mohamed WS, Emad EM. Neutrophil–lymphocyte ratio and response to plasmapheresis in Guillain–Barré syndrome: a prospective observational study. Egypt J Neurol Psychiatry Neurosurg. 2020a; 56 (1). Available in: https://doi.org/10.1186/s41983-020-0154-z

4. Ramakrishnan S, Mustare V, Philip M, Thennarasu K, Periyavan S. Treatment-related fluctuations in guillain barre syndrome and the conundrum of additional cycles of plasmapheresis. Ann Indian Acad Neurol. 2017; 20 (4): 372-377. Available in: https://doi.org/10.4103/aian.aian_242_17

5. Rebolledo-García D, González-Vargas PO, Salgado-Calderón I. Síndrome de Guillain-Barré: viejos y nuevos conceptos. Med Int Méx. 2018; 34 (1): 72-81. Disponible en: https://doi.org/10.24245/mim.v34i1.1922

6. Stoian A, Serban G, Bajko Z, Andone S, Mosora O, Balasa A. Therapeutic plasma exchange as a first-choice therapy for axonal Guillain-Barré syndrome: a case-based review of the literature (Review). Exp Ther Med. 2021; 21 (3): 265. Available in: https://doi.org/10.3892/etm.2021.9696

7. Winer JB. Guillain Barré syndrome. Mol Pathol. 2001; 54 (6): 381-385.

8. Yuki N, Hartung HP. Guillain-Barré syndrome. N Engl J Med. 2012; 366 (24) :2294-304. doi: 10.1056/NEJMra1114525. Erratum in: N Engl J Med. 2012; 367 (17): 1673. Available in: https://doi.org/10.1056/nejmra1114525